Publications by authors named "Mark H Moss"

Background: Thymic stromal lymphopoietin (TSLP) has been shown to play a central role in the initiation and persistence of allergic responses.

Objective: We evaluated whether tezepelumab, a human monoclonal anti-TSLP antibody, improved the efficacy of subcutaneous allergen immunotherapy (SCIT) and promoted the development of tolerance in patients with allergic rhinitis.

Methods: We conducted a double-blind parallel design trial in patients with cat allergy.

View Article and Find Full Text PDF

Background: Prostaglandin D receptor 2 (DP) antagonists inhibit prostaglandin D-induced effects, including recruitment and activation of cells driving asthma pathogenesis. However, challenges identifying target population and end points persist.

Research Question: What is the effect of the DP antagonist GB001 on asthma worsening in patients with moderate to severe eosinophilic asthma?

Study Design And Methods: In this phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, parallel-group, multicenter study, GB001 or placebo was added to standard-of-care treatment in patients with moderate to severe asthma with a blood eosinophil count ≥ 250 cells/μL.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the combined effects of subcutaneous immunotherapy (SCIT) and Dupilumab on patients with seasonal allergic rhinitis (SAR) who are unresponsive to standard treatments.
  • Although SCIT+Dupilumab did not significantly reduce nasal symptoms compared to SCIT alone, it demonstrated improved treatment tolerability, with fewer patients needing epinephrine rescue and higher rates of achieving the maintenance dose.
  • The results suggest that adding Dupilumab to SCIT may enhance overall patient adherence and comfort without significantly improving immediate allergy response symptoms.
View Article and Find Full Text PDF

Background: Breath-actuated inhalers (BAI) have been developed to simplify the delivery of inhaled medication.

Objective: To evaluate the safety and efficacy of beclomethasone dipropionate hydrofluoroalkane BAI and metered-dose inhaler (MDI) versus placebo in patients who previously used a mid- to high-dose inhaled corticosteroid or inhaled corticosteroid/long-acting beta agonist for persistent asthma.

Methods: This phase III study included five treatment groups: placebo, and four beclomethasone dipropionate groups (BAI 320 μg/day, BAI 640 μg/day, MDI 320 μg/day, and MDI 640 μg/day).

View Article and Find Full Text PDF

Omalizumab has been shown to be effective in chronic urticaria (CU) patients in numerous reports. However, it remains unknown whether there are specific phenotypes of CU that are more responsive to omalizumab therapy. We sought to identify CU phenotypes responsive to treatment with omalizumab by characterizing patients and their response patterns.

View Article and Find Full Text PDF

Background: For children who have uncontrolled asthma despite the use of low-dose inhaled corticosteroids (ICS), evidence to guide step-up therapy is lacking.

Methods: We randomly assigned 182 children (6 to 17 years of age), who had uncontrolled asthma while receiving 100 microg of fluticasone twice daily, to receive each of three blinded step-up therapies in random order for 16 weeks: 250 microg of fluticasone twice daily (ICS step-up), 100 microg of fluticasone plus 50 microg of a long-acting beta-agonist twice daily (LABA step-up), or 100 microg of fluticasone twice daily plus 5 or 10 mg of a leukotriene-receptor antagonist daily (LTRA step-up). We used a triple-crossover design and a composite of three outcomes (exacerbations, asthma-control days, and the forced expiratory volume in 1 second) to determine whether the frequency of a differential response to the step-up regimens was more than 25%.

View Article and Find Full Text PDF

Background: Acute wheezing illnesses in preschoolers require better management strategies to reduce morbidity.

Objectives: We sought to examine the effectiveness of episodic use of an inhaled corticosteroid and a leukotriene receptor antagonist in preschoolers with intermittent wheezing.

Methods: In a randomized, double-blind, placebo-controlled 12-month trial, 238 children aged 12 to 59 months with moderate-to-severe intermittent wheezing received 7 days of either budesonide inhalation suspension (1 mg twice daily), montelukast (4 mg daily), or placebo in addition to albuterol with each identified respiratory tract illness (RTI).

View Article and Find Full Text PDF

Background: More evidence is needed on which to base recommendations for treatment of mild-moderate persistent asthma in school-aged children.

Objective: The Pediatric Asthma Controller Trial (PACT) compared the effectiveness of 3 regimens in achieving asthma control.

Methods: A total of 285 children (ages 6-14 years) with mild-moderate persistent asthma on the basis of symptoms, and with FEV(1) >or= 80% predicted and methacholine FEV(1) PC(20) View Article and Find Full Text PDF

Background: Rush immunotherapy (RIT) presents an attractive alternative to standard immunotherapy. However, RIT carries a much greater risk of acute allergic reactions, including anaphylaxis.

Objectives: We hypothesized that omalizumab, a humanized monoclonal anti-IgE antibody, would be effective in enhancing both safety and efficacy of RIT.

View Article and Find Full Text PDF

Background: Outcome data are needed to base recommendations for controller asthma medication use in school-aged children.

Objective: We sought to determine intraindividual and interindividual response profiles and predictors of response to an inhaled corticosteroid (ICS) and a leukotriene receptor antagonist (LTRA).

Methods: An ICS, fluticasone propionate (100 mug twice daily), and an LTRA, montelukast (5-10 mg nightly, age dependent), were administered to children ages 6 to 17 years with mild-to-moderate persistent asthma using only as-needed bronchodilators in a multicenter, double-masked, 2-sequence, 16-week crossover trial.

View Article and Find Full Text PDF
Immunotherapy: first do no harm.

Immunol Allergy Clin North Am

May 2005

Immunotherapy continues to be a treatment modality that is used most exclusively by allergists. The acceptance of immunotherapy for treating children with allergic rhinitis or asthma has been limited by the lack of adequate numbers of pediatric double-blind, placebo-controlled trials of specific allergen immunotherapy; use of venom immunotherapy is more clearly supported by current data. Children represent a unique group of patients where allergic disease may not only be treated using immunotherapy resulting in reduction of symptoms, signs, and complications of disease, but may also hold the best potential for the evasive goal of prevention of the development of future allergic disease.

View Article and Find Full Text PDF

Background: Responses to inhaled corticosteroids (ICSs) and leukotriene receptor antagonists (LTRAs) vary among asthmatic patients.

Objective: We sought to determine whether responses to ICSs and LTRAs are concordant for individuals or whether asthmatic patients who do not respond to one medication respond to the other.

Methods: Children 6 to 17 years of age with mild-to-moderate persistent asthma were randomized to one of 2 crossover sequences, including 8 weeks of an ICS, fluticasone propionate (100 microg twice daily), and 8 weeks of an LTRA, montelukast (5-10 mg nightly depending on age), in a multicenter, double-masked, 18-week trial.

View Article and Find Full Text PDF